HPV vaccine after cervical lesion treatment
Treatments studied
Part of Cancer clinical trials.
This trial tests whether an HPV vaccine (Gardasil 9) can help women over 45 who still have HPV after treatment for a high-grade cervical lesion. It compares vaccinated and unvaccinated patients to see if vaccination lowers the risk of the lesion coming back.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are a woman over 45 years old
- You had a cone biopsy (conization) to remove a high-grade cervical lesion
- You tested positive for HPV at your 6-12 month checkup after surgery
- You have not had an HPV vaccine before
- You have never had an HPV-related invasive cancer (such as cervical, vaginal, vulvar, anal, or throat cancer)
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether getting the HPV vaccine after treatment for vulvar high-grade lesions can help prevent the lesions from coming back. It is for women who have not been vaccinated before and are about to have treatment for this condition.
This study tests how HPV antibodies work in urine samples from women with HPV16 before and after they get the HPV vaccine (Gardasil 9). It helps researchers understand how the vaccine protects against HPV.
This Phase 3 study tests whether getting the HPV vaccine after a LEEP procedure helps prevent the cervical problem from coming back. You may be eligible if you had a high-grade cervical pre-cancer or very early cancer, and have not had an HPV vaccine before.
This trial tests whether an HPV vaccine (the nonavalent type) can help prevent the same precancerous lesions from coming back after treatment. It is for people who currently have a high-grade HPV-related lesion but have not yet been treated for it.
This Phase 4 study tests whether a 9-type HPV vaccine (9vHPV) can reduce how infectious HPV is and lower the chance of HPV spreading in women who already have HPV16 and/or HPV18. It focuses on specific HPV-positive women recently diagnosed and compares what happens after vaccination.
This trial studies how well the Gardasil-9 HPV vaccine triggers the body’s immune response in people living with HIV. It may help doctors understand the best way to protect against HPV-related cancers and infections in this population.
Hear when a new Cervical Lesion trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.